News

Drug Briefing: Zavegepant

Views: 53     Author: Unibest Industrial     Publish Time: 2024-07-29      Origin: Site

facebook sharing button
twitter sharing button
line sharing button
wechat sharing button
linkedin sharing button
pinterest sharing button
sharethis sharing button


Query Drug:Zavegepant

Query Time:2024-08-26 15:53:36

*** Disclaimer *** The information provided here is sourced from resources such as Drugs.com, the Orange Book, etc., and is auto-generated by the Unibest Digital Center. The content is intended exclusively for pharmaceutical professionals. Unibest does NOT accept legal responsibility for ANY medical actions taken based on this information. ALWAYS consult with your doctor for medical advice. In addition, this product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.


Related Diseases

Extra Information on Drug and Diseases

Drug zavegepant

RXCUI: 2637955

May Treat

  • Migraine without Aura

    This drug could potentially cover 19890986 global Migraine without Aura patients.

    And there could potentially be 235102 annual growth in global Migraine without Aura patient number coverage.

    References:

    • For migraine without aura, the more recent studies of the general adult population indicate lifetime prevalence rates between 6% and 10% for men and between 15% and 26% for women. One–year prevalence rates are between 2% and 15% for men and between 4% and 35% for women. | J. Headache Pain  2001

    • Aura is seen in about 25% of patients with migraines. | StatPearls  2022

    • Migraine is a neurological (brain and nervous system) disorder whose main symptom is intense headaches. There's no cure | WebMD  2024

    • Of all migraineurs, 68.6% had consulted a physician for headache in the previous one year, and only 13.5% had received a physician diagnosis of migraine. | J. Neurol. Sci.  2012

    • Just 13.0% reported current use of daily preventive migraine medication. | J. Neurol.  2007


  • Migraine with Aura

    This drug could potentially cover 5414452 global Migraine with Aura patients.

    And there could potentially be 78368 annual growth in global Migraine with Aura patient number coverage.

    References:

    • Aura is seen in about 25% of patients with migraines. | StatPearls  2022

    • Aura is seen in about 25% of patients with migraines. | StatPearls  2022

    • Migraine is a neurological (brain and nervous system) disorder whose main symptom is intense headaches. There's no cure | WebMD  2024

    • Of all migraineurs, 68.6% had consulted a physician for headache in the previous one year, and only 13.5% had received a physician diagnosis of migraine. | J. Neurol. Sci.  2012

    • Just 13.0% reported current use of daily preventive migraine medication. | J. Neurol.  2007

Similar Drugs

[may_treat] Migraine with Aura

Source MEDRT

[may_treat] Migraine without Aura

Source MEDRT

[Phamacological Category] Calcitonin Gene-related Peptide Receptor Antagonist

Source FDASPL

[Phamacological Category] Calcitonin Gene-related Peptide Receptor Antagonist

Source DAILYMED

[Mechanism of Action] Calcitonin Gene-related Peptide Receptor Antagonists

Source MEDRT

[Mechanism of Action] Calcitonin Gene-related Peptide Receptor Antagonists

Source FDASPL

[Mechanism of Action] Calcitonin Gene-related Peptide Receptor Antagonists

Source DAILYMED

Drug zavegepant hydrochloride

RXCUI: 2637956

May Treat

  • Migraine without Aura

    This drug could potentially cover 19890986 global Migraine without Aura patients.

    And there could potentially be 235102 annual growth in global Migraine without Aura patient number coverage.

    References:

    • For migraine without aura, the more recent studies of the general adult population indicate lifetime prevalence rates between 6% and 10% for men and between 15% and 26% for women. One–year prevalence rates are between 2% and 15% for men and between 4% and 35% for women. | J. Headache Pain  2001

    • Aura is seen in about 25% of patients with migraines. | StatPearls  2022

    • Migraine is a neurological (brain and nervous system) disorder whose main symptom is intense headaches. There's no cure | WebMD  2024

    • Of all migraineurs, 68.6% had consulted a physician for headache in the previous one year, and only 13.5% had received a physician diagnosis of migraine. | J. Neurol. Sci.  2012

    • Just 13.0% reported current use of daily preventive migraine medication. | J. Neurol.  2007


  • Migraine with Aura

    This drug could potentially cover 5414452 global Migraine with Aura patients.

    And there could potentially be 78368 annual growth in global Migraine with Aura patient number coverage.

    References:

    • Aura is seen in about 25% of patients with migraines. | StatPearls  2022

    • Aura is seen in about 25% of patients with migraines. | StatPearls  2022

    • Migraine is a neurological (brain and nervous system) disorder whose main symptom is intense headaches. There's no cure | WebMD  2024

    • Of all migraineurs, 68.6% had consulted a physician for headache in the previous one year, and only 13.5% had received a physician diagnosis of migraine. | J. Neurol. Sci.  2012

    • Just 13.0% reported current use of daily preventive migraine medication. | J. Neurol.  2007

Similar Drugs

[may_treat] Migraine with Aura

Source MEDRT

[may_treat] Migraine without Aura

Source MEDRT

[Mechanism of Action] Calcitonin Gene-related Peptide Receptor Antagonists

Source MEDRT

Orange Book

[Last update] 2024-08-09

Labelers

Zavegepant's Innovator is PFIZER INC

Drug Products

The unique dosage forms from the innovator include:1. SPRAY, METERED;NASAL.

Index Route Brand Name Labeler Approval Date Dosage
1 SPRAY, METERED;NASAL ZAVZPRET PFIZER INC Mar 9, 2023 EQ 10MG BASE/SPRAY

Drug Patents

This drug still has 2 effective patents.

Patent Number Submission Date Expiration Date Drug Substance Patent? Drug Product Patent?
8481546 Apr 6, 2023 Oct 7, 2031 Y Y
7220862 Apr 6, 2023 Jan 21, 2024 Y Y

Zavegepant Patent Scope

Related Company's Product Pipelines

The innovator PFIZER INC's portolio contains products with the following 32 API(s): NIFEDIPINE, NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE, IBUTILIDE FUMARATE, METHYLPREDNISOLONE ACETATE, PALBOCICLIB, CLINDAMYCIN PALMITATE HYDROCHLORIDE, POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE, CLINDAMYCIN PHOSPHATE, ZALEPLON, RIFABUTIN, TALAZOPARIB TOSYLATE, RITLECITINIB TOSYLATE, TESTOSTERONE CYPIONATE, TRANEXAMIC ACID, THIOTHIXENE HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE, NICOTINE, ALPROSTADIL, CEFOPERAZONE SODIUM, MEDROXYPROGESTERONE ACETATE, DISOPYRAMIDE PHOSPHATE, FLUCONAZOLE, THIOTHIXENE, METRONIDAZOLE, LINEZOLID, ESTRADIOL CYPIONATE, DIFLORASONE DIACETATE, BENZONATATE, DINOPROSTONE

The above products are related to 218 diseases: Angina, Stable, Hypertension, Angina Pectoris, Variant, Alcoholism, Drug Overdose, Opioid-Related Disorders, Pain, Postoperative, Multiple Myeloma, Soft Tissue Neoplasms, Breast Neoplasms, Urinary Bladder Neoplasms, Liver Neoplasms, Leukemia, Myeloid, Acute, Hodgkin Disease, Prostatic Neoplasms, Wilms Tumor, Osteosarcoma, Testicular Neoplasms, Ovarian Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Mesothelioma, Gastrointestinal Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Neuroblastoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Atrial Fibrillation, Atrial Flutter, Rheumatic Diseases, Colitis, Ulcerative, Uveitis, Sarcoidosis, Multiple Sclerosis, Leukemia, Pemphigus, Hypercalcemia, Erythema Multiforme, Inflammation, Lupus Erythematosus, Systemic, Tuberculosis, Pulmonary, Thyroiditis, Hematologic Diseases, Graft vs Host Disease, Serum Sickness, Mycosis Fungoides, Synovitis, Adrenal Insufficiency, Arthritis, Rheumatoid, Berylliosis, Asthma, Neurologic Manifestations, Dermatitis Herpetiformis, Respiratory Distress Syndrome, Brain Neoplasms, Spondylitis, Ankylosing, Dermatitis, Atopic, Arthritis, Gouty, Nephrotic Syndrome, Breast Neoplasms, Actinomycetales Infections, Streptococcal Infections, Bacteroides Infections, Acne Vulgaris, Vaginosis, Bacterial, Toxoplasmosis, Pneumonia, Pneumocystis, Endocarditis, Bacterial, Staphylococcal Infections, Hypertension, Edema, Heart Failure, Liver Cirrhosis, Glomerulonephritis, Renal Insufficiency, Nephrotic Syndrome, Urinary Retention, Prostatic Hyperplasia, Raynaud Disease, Hypertension, Actinomycetales Infections, Streptococcal Infections, Bacteroides Infections, Acne Vulgaris, Vaginosis, Bacterial, Toxoplasmosis, Pneumonia, Pneumocystis, Endocarditis, Bacterial, Staphylococcal Infections, Sleep Initiation and Maintenance Disorders, Mycobacterium avium-intracellulare Infection, Tuberculosis, Pulmonary, Breast Neoplasms, Alopecia Areata, Hypogonadism, Breast Neoplasms, Puberty, Delayed, Subarachnoid Hemorrhage, Oral Hemorrhage, Blood Coagulation Disorders, Inherited, Schizophrenia, Psychotic Disorders, Lymphoma, Leukemia, Colonic Neoplasms, Breast Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Neoplasm Metastasis, Carcinoma, Non-Small-Cell Lung, Rectal Neoplasms, Hypercholesterolemia, Hyperlipoproteinemias, Coronary Artery Disease, Hypertriglyceridemia, Diarrhea, Enterocolitis, Pseudomembranous, Actinomycetales Infections, Streptococcal Infections, Bacteroides Infections, Acne Vulgaris, Vaginosis, Bacterial, Toxoplasmosis, Pneumonia, Pneumocystis, Endocarditis, Bacterial, Staphylococcal Infections, Substance Withdrawal Syndrome, Colitis, Ulcerative, Tobacco Use Disorder, Ductus Arteriosus, Patent, Hypoplastic Left Heart Syndrome, Pulmonary Valve Stenosis, Impotence, Vasculogenic, Hypertension, Pulmonary, Tetralogy of Fallot, Tricuspid Atresia, Aortic Arch Syndromes, Aortic Coarctation, Escherichia coli Infections, Salmonella Infections, Klebsiella Infections, Pneumonia, Bacterial, Streptococcal Infections, Proteus Infections, Pseudomonas Infections, Soft Tissue Infections, Urinary Tract Infections, Haemophilus Infections, Bone Diseases, Infectious, Serratia Infections, Genital Diseases, Female, Skin Diseases, Bacterial, Staphylococcal Infections, Carcinoma, Renal Cell, Amenorrhea, Breast Neoplasms, Endometrial Hyperplasia, Hypoventilation, Uterine Hemorrhage, Pregnancy, Endometrial Neoplasms, Ventricular Premature Complexes, Tachycardia, Ventricular, Atrial Fibrillation, Atrial Flutter, Atrial Premature Complexes, Coccidioidomycosis, AIDS-Related Opportunistic Infections, Blastomycosis, Candidiasis, Chronic Mucocutaneous, Pneumonia, Candidiasis, Vulvovaginal, Urinary Tract Infections, Histoplasmosis, Fungemia, Candidiasis, Oral, Meningitis, Cryptococcal, Schizophrenia, Psychotic Disorders, Amebiasis, Surgical Wound Infection, Abscess, Meningitis, Bacterial, Bacteroides Infections, Rosacea, Sepsis, Helicobacter Infections, Giardiasis, Enterocolitis, Pseudomembranous, Vaginosis, Bacterial, Trichomonas Vaginitis, Endocarditis, Bacterial, Trichomonas Infections, Pneumonia, Bacterial, Streptococcal Infections, Soft Tissue Infections, Skin Diseases, Bacterial, Staphylococcal Infections, Hot Flashes, Primary Ovarian Insufficiency, Hypogonadism, Breast Neoplasms, Prostatic Neoplasms, Osteoporosis, Postmenopausal, Menopause, Premature, Menorrhagia, Pruritus, Leg Dermatoses, Inflammation, Hand Dermatoses, Scalp Dermatoses, Foot Dermatoses, Facial Dermatoses, Cough, Hiccup, Uterine Neoplasms, Gestational Trophoblastic Disease, Fetal Death

PFIZER INC Diseases Covered